U.S. Healthtech Stock News

CleanSpark, Inc. has already reported unaudited October 2025 production of 587 Bitcoin and fiscal 2025 results showing revenue of US$766.31 million and net income of US$364.46 million, marking a major turnaround from the prior year's loss. Alongside record profitability, the company is expanding into AI and high-performance computing while holding 13,054 Bitcoin and funding growth through US$1.15 billions in zero-coupon convertible notes and large-scale share repurchases. We’ll now examine...

AutoZone (AZO) opened fiscal Q1 2026 with total revenue of $4.6 billion and basic EPS of $31.88, setting the stage against a backdrop where trailing twelve month revenue sits at $19.3 billion and EPS at $147.34. Over recent quarters the company has seen revenue move from $6.2 billion in Q4 2024 to $6.2 billion in Q4 2025 and then to $4.6 billion in Q1 2026, while quarterly EPS tracked from $53.0 to $50.0 and now $31.9, leaving investors weighing solid top line scale against signs of...

Omnicell recently launched Omnicell Titan XT in the United States, an enterprise-grade automated dispensing system powered by its cloud-based, HITRUST-certified OmniSphere platform to unify medication management across health systems. The system’s AI-enabled inventory intelligence and embedded FiveRights safety safeguards position Titan XT as a platform play aimed at reducing medication errors and optimizing pharmacy and nursing workflows across entire hospital networks. Next, we’ll examine...

Wondering if Blue Owl Capital is a bargain or a value trap at around $16 a share? You are not alone, and this is exactly the kind of stock where a closer look at valuation can really pay off. The share price has bounced about 6.6% over the last week and 3.8% over the past month, but that still sits against a much tougher backdrop with the stock down 32.1% year to date and 28.3% over the last year. Even so, the 3 year and 5 year returns are 59.3% and 86.7% respectively. Some of this recent...

Flowers Foods (FLO) has been sliding this year, and that weak share performance is exactly why the stock is getting fresh attention from value focused investors looking for a reset. See our latest analysis for Flowers Foods. That drop has left the share price at about $10.71, and with a roughly 48% year to date share price return decline and a similar slide in the one year total shareholder return, momentum clearly looks to be fading rather than stabilising. If Flowers Foods' slump has you...

If you are wondering whether PTC is quietly becoming a bargain or if the market is rightly cautious at today’s price, you are in the right place to unpack what the numbers are really saying about its value. Despite a solid 40.6% gain over three years and 53.2% over five years, the stock is down 12.6% over the last year and 4.7% year to date, suggesting sentiment has cooled even as the longer term picture still looks constructive. Recent headlines have focused on PTC’s continued push in...

IREN (NasdaqGS:IREN) just pushed through a multi billion dollar mix of convertible notes and new equity, a move that hit the stock but is central to funding its AI and data center pivot. See our latest analysis for IREN. Those hefty offerings landed on a stock that has already been on a wild ride, with a 30 day share price return of minus 25.71% but a 90 day share price return of 53.49%, and a three year total shareholder return above 3,100%. This suggests long term momentum is still very...

Nuvation Bio (NUVB) has been on traders radar after two catalysts landed almost back to back: encouraging phase 2 data for Safusidenib in IDH1 mutant gliomas, and China reimbursement news for partner drug taletrectinib. See our latest analysis for Nuvation Bio. Those twin catalysts have lit a fire under sentiment, with an 81.4 percent 1 month share price return and a 206.43 percent 1 year total shareholder return suggesting momentum is clearly building rather than fading. If Nuvation Bio’s...

InnoScience (Suzhou) Technology Holding Co., Ltd. recently announced a cooperation with onsemi to combine its 8-inch GaN-on-silicon manufacturing with onsemi’s packaging and system integration strengths, aiming to accelerate GaN deployment in areas such as new energy vehicles, AI, data centers and industrial applications, with the partnership expected to generate hundreds of millions of US dollars in future GaN sales. This agreement highlights how onsemi is deepening its exposure to wide...

Immunocore Holdings (IMCR) has been in focus after its Jefferies London Healthcare Conference update, where management walked investors through late stage progress for KIMMTRAK in cutaneous melanoma and its PRAME bispecific program. See our latest analysis for Immunocore Holdings. That conference update seems to have given the stock fresh energy, with a 1 month share price return of 13.76 percent contributing to a 27.80 percent year to date share price gain. However, the 3 year total...

In the third quarter, New York-based Harvey Partners acquired 318,000 Materion shares for about US$38.4 million, a new position equal to roughly 3.4% of its U.S. equity portfolio, following an SEC filing dated 14 November. This investment arrived shortly after Materion reported strong third-quarter operational results, including margin expansion in its electronic materials and precision optics businesses, highlighting growing institutional interest in the company’s core profit drivers. We’ll...

In recent months, Humana cut its full-year earnings outlook as ongoing pressure in its Medicare Advantage business weighed on profitability expectations. At the same time, the company’s talks on a potential Mark Cuban pharmacy partnership spotlight how simplifying the drug supply chain could reshape Humana’s broader healthcare services ambitions. We’ll now examine how Humana’s lowered earnings outlook and potential Mark Cuban pharmacy tie-up may reshape the company’s investment narrative...

Select Medical Holdings (SEM) has quietly outperformed the broader market over the past 3 months, with the stock up around 15% and roughly 12% over the past month, despite weaker year to date returns. See our latest analysis for Select Medical Holdings. That recent 30 day share price return of nearly 12% looks more like a rebound than a blip. This is especially true when set against a year to date share price decline of around 21% and a one year total shareholder return of roughly minus 24%...

Ondas Holdings (ONDS) just delivered a big revenue jump, raised its full year outlook, and backed it up with new government drone contracts and a strategic Ukrainian UAS investment, giving investors fresh reasons to revisit the stock. See our latest analysis for Ondas Holdings. The market seems to be waking up to this story, with a 30 day share price return of 55.25 percent and a year to date share price gain of 242.97 percent. The 1 year total shareholder return of 1009.2 percent suggests...

In recent days, 1st Choice Delivery announced that it has been acquired by Lanter Delivery Systems, a portfolio company of Audax Private Equity, with Houlihan Lokey serving as financial advisor and facilitating Northern Pacific Group’s exit from its 2017 investment. Alongside this client milestone, fresh Morgan Stanley commentary highlighting Houlihan Lokey’s potential to benefit from a faster-than-expected rebound in sponsor activity has drawn investor attention to the firm’s role in...

If you have been wondering whether Taiwan Semiconductor Manufacturing is still a smart buy after its huge run, you are not alone. That is exactly what this article will dig into. The stock has climbed 3.3% over the last week, 5.4% over the past month, and 49.8% year to date, building on gains of 59.0% over 1 year, 289.8% over 3 years, and 207.1% over 5 years. Recent headlines have highlighted TSM's central role in advanced chip manufacturing for AI data centers and leading edge smartphone...

Fulcrum Therapeutics (FULC) has just delivered early PIONEER trial data that moved the needle, with pociredir driving meaningful fetal hemoglobin gains in sickle cell patients and setting up the stock for a very different conversation. See our latest analysis for Fulcrum Therapeutics. The PIONEER update has clearly reset expectations. Fulcrum’s 1 day share price return of 45.96% has helped drive a 30 day share price return of 70.25% and a 1 year total shareholder return of 223.94%, suggesting...

American Airlines Group (AAL) heads into its December 3 presentation at the Goldman Sachs Industrials and Materials Conference with sentiment quietly improving as big money starts positioning for a potential airline recovery in 2026. See our latest analysis for American Airlines Group. That cautious optimism is starting to show up in the tape, with American’s 90 day share price return of 16.46 percent and 30 day share price return of 8.86 percent contrasting with a still negative year to date...

DocuSign (DOCU) just doubled down on its European ambitions, committing EUR 4.5 million to expand its AI Centre of Excellence in Dublin as it celebrates ten years of growth and innovation in Ireland. See our latest analysis for DocuSign. That push into Dublin comes on the heels of stronger third quarter results, upbeat revenue guidance, and a sizeable share buyback. However, the 1 year total shareholder return of minus 31.1% and 5 year total shareholder return of minus 71.74% show sentiment...

Crescent Energy (CRGY) is back in focus after Q3 results showed revenue up about 16% year over year, yet still shy of forecasts, and management lifted full year capital spending guidance on the back of efficiencies and divestiture cash. See our latest analysis for Crescent Energy. The mixed Q3 update seems to be nudging sentiment off the lows, with a roughly 21% 3 month share price return contrasting against a still weak 1 year total shareholder return of around negative 28%. This suggests...

Constellium SE has completed and inaugurated new finishing lines at its Singen plant in Germany, finalizing the EUR30 million partnership investment with Lotte Infracell to supply high-quality aluminum foilstock for European battery applications, supported by upgraded logistics, safety systems, and on-site solar power generation. This expansion strengthens Constellium's position in the growing battery materials supply chain while showcasing its focus on productivity, safety, and lower-carbon...

In early December 2025, Braze announced that its BrazeAI Decisioning Studio is now available on Google Cloud Marketplace, enabling customers to deploy AI-driven, reinforcement learning–based personalization directly within their Google Cloud environments using first-party data. This move not only simplifies access to Braze’s AI decisioning for enterprise clients, but also deepens its integration with Google’s cloud and data tools, potentially making Braze a more embedded part of customers’...

Earlier this month, Liberty Sports Group and Front Row Hospitality announced a multi-year deal making Shift4 Payments the exclusive technology partner across Liberty’s growing North American sports, entertainment, and live experience portfolio, while Shift4 also completed a €435 million 5.500% senior unsecured notes offering due 2033, priced at 102.5% of principal. This combination of an exclusive venue-technology mandate and fresh euro-denominated funding highlights Shift4’s push to deepen...

Amylyx Pharmaceuticals (AMLX) has quietly staged a sharp rebound this year, with the stock up roughly 250% year to date and about 180% over the past year, drawing fresh attention from biotech investors. See our latest analysis for Amylyx Pharmaceuticals. The recent pullback, with a 1 day share price return of minus 3.7 percent and a 7 day share price return of minus 4.0 percent, looks more like a pause in what has been strong upward momentum, given the 30 day share price return of 11.1...